Equillium
About: Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Employees: 35
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
13% more funds holding
Funds holding: 24 [Q1] → 27 (+3) [Q2]
0.06% more ownership
Funds ownership: 24.32% [Q1] → 24.38% (+0.06%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
19% less capital invested
Capital invested by funds: $3.39M [Q1] → $2.74M (-$649K) [Q2]
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Financial journalist opinion
Based on 4 articles about EQ published over the past 30 days
